# Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

> **NCT00467077** · PHASE2 · TERMINATED · sponsor: **California Cancer Consortium** · enrollment: 21 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** PEG-interferon alfa-2b
- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT00467077
- **Lead sponsor:** California Cancer Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Protocol was closed due to slow accrual.
- **Last updated:** 2017-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00467077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00467077, "Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00467077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*